Septerna, Inc.

NASDAQ:SEPN

Biotechnology

Healthcare
$39.45 -2.04%

-$0.73 today

Market cap
$1.88B
Beta
2.38
P/E (TTM)
-43.6
EPS (TTM)
-$0.81
52W Low $9.96High $37.32

Volume 0.30M

Average 0.32M

SEPN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Septerna, Inc.NASDAQ: SEPN

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares of 46.91M shares rose 5.8% year over year, behind the +9.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 4.2% from the prior quarter.

Context

  • Weighted avg shares increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +9.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
46.91M+4.2% QoQ
Last fiscal yearDec 2025
44.26M+19.0% YoY
LTMSep 2026
45.24M+9.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year+19.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
44.26M USD
Year-over-year change
+19.0%
2-year CAGR
+50.7%

Weighted Avg Shares vs competitors

How SEPN compares with its peers on the latest reported figures

  • SEPN's LTM Sep 2026 weighted avg shares of 45.24M shares is the 5th highest of the 7 companies compared; the peer median is 51.55M shares.
  • Its year-over-year change of +9.8% is the 5th highest of 6, against a peer median of +30.1%.
SEPN Competitors Peer median
Weighted Avg Shares for SEPN and competitors
Company Period LTM YoY 3-year CAGR
KLRAKailera Therapeutics, Inc.FY2025117.95M ——
GPCRStructure Therapeutics Inc.LTM Jun 202665.7M +14.4%+17.4%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
SEPNSepterna, Inc.LTM Sep 202645.24M +9.8%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
VTVTvTv Therapeutics Inc.LTM Mar 20267.87M +30.1%+63.7%
Peer median (excluding SEPN) 51.55M+30.1%+17.4%

Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue151K1.08M45.95M
Cost of Revenue000
Gross Profit151K1.08M45.95M
Gross Margin100.0%100.0%100.0%
Research & Development35.98M65.34M97.58M
Selling, General & Admin9.72M16.56M29.16M
Operating Expenses(1.92M)81.9M126.75M
Depreciation & Amortization848K1.4M1.6M
EBITDA(44.7M)(70.9M)(47.26M)
EBITDA Margin-29604.0%-6594.9%-102.9%
Operating Income2.08M(80.82M)(80.8M)
Operating Margin1374.2%-7518.4%-175.8%
Interest Income2.79M8.62M19.53M
Interest Expense000
Other Income / Expenses2.8M8.53M31.93M
Income Before Tax4.87M(72.3M)(48.87M)
Pre-Tax Margin3225.8%-6725.2%-106.3%
Income Tax Expense691K(498K)12K
Net Income4.18M(71.8M)(48.88M)
Net Margin2768.2%-6678.9%-106.4%
EPS (Basic)0.03(1.93)(1.10)
EPS (Diluted)0.03(1.93)(1.10)
Weighted Avg Shares19.5M37.19M44.26M
Weighted Avg Shares (Diluted)19.5M37.19M44.26M

Septerna, Inc.

NASDAQ:SEPN

Intrinsic Alpha fair value

Locked

Current Price

$39.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.